Back to Newsroom

Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage

LOS ANGELES, Calif., Mar. 10, 2015 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiation of a Phase II trial of Puma’s investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer.

Click here to read the full release